This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Yumanity Therapeutics Valuation

Is 8IY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8IY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 8IY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 8IY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8IY?

Key metric: As 8IY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8IY. This is calculated by dividing 8IY's market cap by their current revenue.
What is 8IY's PS Ratio?
PS Ratio	29.7x
Sales	US$4.84m
Market Cap	US$143.63m

8IY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	28x
Enterprise Value/EBITDA	-5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 8IY's PS Ratio compare to its peers?

The above table shows the PS ratio for 8IY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.3x
HPHA Heidelberg Pharma	12x	16.6%	€102.1m
MDG1 Medigene	3x	16.1%	€22.5m
2INV 2invest	8.1x	n/a	€62.7m
FYB Formycon	14x	33.4%	€848.4m
8IY Yumanity Therapeutics	29.7x	n/a	€143.6m

Price-To-Sales vs Peers: 8IY is expensive based on its Price-To-Sales Ratio (29.7x) compared to the peer average (16.8x).

Price to Sales Ratio vs Industry

How does 8IY's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 8IY is expensive based on its Price-To-Sales Ratio (29.7x) compared to the European Biotechs industry average (12.2x)

Price to Sales Ratio vs Fair Ratio

What is 8IY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8IY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	29.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8IY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%